Jhen-Hao Jhan1, Hsin-Chih Yeh2, Yu-Han Chang3, Shiao-Jin Guu1, Wen-Jeng Wu2, Yii-Her Chou4, Ching-Chia Li5. 1. Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. 2. Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; Department of Urology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan; Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. 3. Management Offices, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan. 4. Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. 5. Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. Electronic address: ccli1010@hotmail.com.
Abstract
INTRODUCTION: Androgen-deprivation therapy (ADT) is important in the treatment of prostate cancer. However, the relationship between ADT and the risk of diabetes remains unclear, and the association between duration and types of ADT has not been fully investigated. AIM: To examine the risk of developing type 2 diabetes mellitus (T2DM) in men who underwent ADT for prostate cancer. METHODS: Data were collected retrospectively from the Longitudinal Health Insurance Database of Taiwan. In total, 4604 prostate cancer patients ≥40 years old who underwent ADT were included in the study cohort, and 4604 prostate cancer patients without ADT were included as controls, after adjusting for age and other comorbidities. RESULTS: During the four-year follow-up period, the incidence of new-onset T2DM was 27.49 and 11.13 per 1000 person-years in the ADT and ADT-never cohorts, respectively. The ADT cohort was 2.19 times more likely to develop T2DM than the control group (95% CI 1.90-2.53, P < 0.001). Furthermore, the association was particularly striking in the subgroup of patients receiving complete androgen blockade (adjusted HR 2.33, 95% CI 1.96-2.78, P < 0.001). CONCLUSIONS: Men with prostate cancer who received ADT are at risk for developing diabetes.
INTRODUCTION: Androgen-deprivation therapy (ADT) is important in the treatment of prostate cancer. However, the relationship between ADT and the risk of diabetes remains unclear, and the association between duration and types of ADT has not been fully investigated. AIM: To examine the risk of developing type 2 diabetes mellitus (T2DM) in men who underwent ADT for prostate cancer. METHODS: Data were collected retrospectively from the Longitudinal Health Insurance Database of Taiwan. In total, 4604 prostate cancerpatients ≥40 years old who underwent ADT were included in the study cohort, and 4604 prostate cancerpatients without ADT were included as controls, after adjusting for age and other comorbidities. RESULTS: During the four-year follow-up period, the incidence of new-onset T2DM was 27.49 and 11.13 per 1000 person-years in the ADT and ADT-never cohorts, respectively. The ADT cohort was 2.19 times more likely to develop T2DM than the control group (95% CI 1.90-2.53, P < 0.001). Furthermore, the association was particularly striking in the subgroup of patients receiving complete androgen blockade (adjusted HR 2.33, 95% CI 1.96-2.78, P < 0.001). CONCLUSIONS:Men with prostate cancer who received ADT are at risk for developing diabetes.
Authors: Andras Franko; Lucia Berti; Alke Guirguis; Jörg Hennenlotter; Robert Wagner; Marcus O Scharpf; Martin Hrabĕ de Angelis; Katharina Wißmiller; Heiko Lickert; Arnulf Stenzl; Andreas L Birkenfeld; Andreas Peter; Hans-Ulrich Häring; Stefan Z Lutz; Martin Heni Journal: Genes (Basel) Date: 2020-10-07 Impact factor: 4.096
Authors: Ara Jo; Lisa Scarton; LaToya J O'Neal; Samantha Larson; Nancy Schafer; Thomas J George; Juan M Munoz Pena Journal: Cancer Med Date: 2020-12-23 Impact factor: 4.452
Authors: E Lin; Hans Garmo; Mieke Van Hemelrijck; Jan Adolfsson; Pär Stattin; Björn Zethelius; Danielle Crawley Journal: BMC Cancer Date: 2021-11-22 Impact factor: 4.430
Authors: Andras Franko; Lucia Berti; Jörg Hennenlotter; Steffen Rausch; Marcus O Scharpf; Martin Hrabĕ de Angelis; Arnulf Stenzl; Andreas L Birkenfeld; Andreas Peter; Stefan Z Lutz; Hans-Ulrich Häring; Martin Heni Journal: J Pers Med Date: 2020-09-12